The role of calcium antagonists in patients with chronic renal failure

Pediatric Nephrology

Volumn 20, Issue 9, 2005, Pages 1208-1213

  Rahn, Karl Heinz ^a  

^a INST OF REPRO MED OF THE UNIV   (Germany)

Author keywords

Calcium antagonists; Cardiovascular events; Hypertension; Nephroprotection; Renal failure

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD UROLOGY; CHILDHOOD DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPERTENSION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CHILD; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 24044510449     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-005-1982-x     Document Type: Article

References (37)

1. US Renal data system (1999) USRDS 1999 Annual Data Report, Bethesda, MD, USA
2. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Int Med 134:629-636 1:CAS:528:DC%2BD3MXjsV2ms7Y%3D
3. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold L, Wedel H, Zanchetti A (2001) Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 12:218-225 1:STN:280:DC%2BD3M7mt1CjsQ%3D%3D
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo jr JL, Jones DW, Materson BJ, Oparil S, Wright jr JT, Roccella EJ (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289:2560-2572 10.1001/jama.289.19.2560
5. Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053 12777938
6. Cristofori P, Lanzoni A, Quartaroli M, Pastorino AM, Zancanaro C, Cominacini L, Gaviraghi G, Turton J (2000) The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens 18:1429-1438 10.1097/ 00004872-200018100-00010
7. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P (2002) Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106:2422-2427 10.1161/ 01.CIR.0000039288.86470.DD
8. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CA (1990) Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 335:827-838 10.1016/0140-6736(90)90944-Z
9. Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535 10.1016/S0140-6736(03)14739-3
10. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C (2002) Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 61:2157-2164 10.1046/ j.1523-1755.2002.00355.x
11. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snappin SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869 10.1056/NEJMoa011161
12. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860 10.1056/NEJMoa011303
13. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers, G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359:995-1003 10.1016/S0140-6736(02)08089-3
14. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomised double-blind intervention trial. J Hypertens 21:875-886 10.1097/ 00004872-200305000-00011
15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363:2022-2031 10.1016/S0140-6736(04)16451-9
16. Weber MA, Julius J, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363:2049-2051 10.1016/S0140-6736(04)16456-8
17. Yusuf S, Sleight P, Dagenais G, Montague T, Bosch J, Pogue J, Taylor W, Sardo L (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145-153 10.1056/NEJM200001203420301
18. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, De Jong PE, De Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS (2001) Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131-1140 10.1046/ j.1523-1755.2001.0600031131.x
19. Agadoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek DA, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CL, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller III ER, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright jr JT, Yu S (2001) Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 285:2719-2728 10.1001/jama.285.21.2719
20. Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106:672-678 10.1161/01.CIR.0000024416.33113.0A
21. Ruggenenti P, Fassi A, Parvanova Ilieva A, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951 10.1056/ NEJMoa042167
22. Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285:685-688 1:STN:280:Bi2B2MfitVA%3D
23. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting- enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462 10.1056/NEJM199311113292004
24. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952-1961 10.1056/NEJMoa042274
25. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945 10.1056/ NEJM199604113341502
26. Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M, Zoccali C, Scolari F, Maggiore Q, Tognoni G, Remuzzi G (1997) Randomised placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy. Lancet 349:1857-1863 10.1016/ S0140-6736(96)11445-8
27. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364 10.1016/S0140-6736(98)10363-X
28. Hilgers KF, Dötsch J, Rascher W, Mann JFE (2004) Treatment strategies in patients with chronic renal disease: ACE-inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 19:956-961 10.1007/s00467-004-1554-5
29. Wright jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek DA, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 288:2421-2431 10.1001/jama.288.19.2421
30. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, Saul JP (2004) A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 145:353-359 10.1016/ j.jpeds.2004.04.009
31. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, Tou, C, Kilbaner M (2003) Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 18:548-553 12700955
32. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660-665 10.1161/01.CIR.0000138104.83366.E9
33. Scharer K, Alatas H, Bein G (1977) The treatment of renal hypertension with verapamil in childhood. Monatsschr Kinderheilk 125:706-712 1:STN:280:CSiB2MvntVA%3D
34. Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S (2002) Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 17:35-40 10.1007/s004670200006
35. Flynn JT, Warnick SJ (2002) Isradipine treatment of hypertension in children: A single center experience. Pediatr Nephrol 17:748-753 10.1007/ s00467-002-0939-6
36. Von Vigier RO, Franscini LMD, Bianda NDF, Pfister R, Aebischer CC, Bianchetti MG (2001) Antihypertensive efficacy of amlodipine in children with chronic renal diseases. J Hum Hypertens 15:387-391 10.1038/ sj.jhh.1001203
37. Wühl E, Mehls O, Schaefer F, and the ESCAPE Trial Group (2004) Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 66:768-776 10.1111/j.1523-1755.2004.00802.x